Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 175 participants.

Also called NCT03603912

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 175 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03603912
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03603912. Randomized; single masking; primary purpose treatment. Start 2018-08-24 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
Acronym
TRIM-AF
Intervention (Drug)
Metformin
Intervention (Behavioral)
Lifestyle/Risk Factor Modification
Lead sponsor
Mina Chung, MD (class: other)
Collaborator
American Heart Association (class: other)
Collaborator
The Cleveland Clinic (class: other)

Record details

Record id
cardio:ct-nct03603912
Content hash
559f127b231480a14a7b49edae30461e82412fc7ee417d7401c69228942ab3e3